Open framework agreement on pharmaceutical discounts pursuant to § 130a (8) SGB V with the possibility of joining at any time, so-called admission model 2026-05

… limit by which the tender must be valid" is only due to the general scheme of this form. Contractual partners can become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act (AMG). The contract is concluded or acceded to by completing the required self-declarations or supporting documents as well as the contract(s) either: a) Handwritten signature (written form according to § 126 BGB) by post or b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to [email protected] to be sent to KBS. The earliest start date of the contract is 01.06.2026, provided that the contract and the required declarations or evidence have been received by the KBS by 05.05.2026 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or proofs by the KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the following month. Contracts shall terminate automatically, without any need for termination, as soon as the active substance(s) or combination(s) of active substance(s) have been contracted through a formal procurement procedure. The deadline for the receipt of accessions is 05.04.2028. In any case, the contracts end on 31.05.2028. · The purpose of this notice is to conclude agreements on the active substance ‘Bimatoprost 0,1mg, pharmaceutical form: ATR (ATC code: S01EE03)’ with pharmaceutical companies within the meaning of Section 130a(8), first sentence, of the Social Code, Book 5 (SGB V) (discount contracts). Pursuant to the first sentence of Paragraph 130a(8) of the SGB V, the invitation to participate is addressed only to pharmaceutical entrepreneurs or groups of employees of pharmaceutical entrepreneurs within the meaning of Paragraph 4(18) of the Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/join/discount contracts with conditions fixed and non-negotiable for all participants, including the amount of the discount. The corresponding information under point 2.1 "Type of procedure" and under point 5.1.12 "Condition for awarding the contract _here: The time limit by which the tender must be valid" is only due to the general scheme of this form. Contractual partners can become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act (AMG). The contract is concluded or acceded to by completing the required self-declarations or supporting documents as well as the contract(s) either: a) Handwritten signature (written form according to § 126 BGB) by post or b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to [email protected] to be sent to KBS. The earliest start date of the contract is 01.06.2026, provided that the contract and the required declarations or